Critical Reviews in Oncology / Hematology
Volume 75, Issue 1 , Pages 70-77 , July 2010

Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology

  • Benoit Beuselinck

      Affiliations

    • University Hospitals Leuven, Catholic University Leuven, Medical Oncology Department, Belgium
    • ,
  • Hans Wildiers

      Affiliations

    • University Hospitals Leuven, Catholic University Leuven, Medical Oncology Department, Belgium
    • ,
  • Wim Wynendaele

      Affiliations

    • Medical Oncology Departments of Algemeen Ziekenhuis Imelda, Bonheiden, Belgium
    • ,
  • Luc Dirix

      Affiliations

    • Algemeen Ziekenhuis St-Augustinus, Wilrijk, Belgium
    • ,
  • Jean-Pierre Kains

      Affiliations

    • Hôpitaux Iris Sud, Ixelles, Belgium
    • ,
  • Robert Paridaens

      Affiliations

    • University Hospitals Leuven, Catholic University Leuven, Medical Oncology Department, Belgium
    • Corresponding Author InformationCorresponding author at: University Hospitals Leuven, Katholieke Universiteit Leuven, Herestraat 49, 3000 Leuven, Belgium. Tel.: +32 16 34 69 00; fax: +32 16 34 69 01.

,Accepted 2 July 2009.

References 

  1. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23:5542–5551
  2. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to Trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol. 2008;26:1642–1649
  3. Perez E, Vogel C, Irwin D, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001;19:4216–4223
  4. Baltali E, Altundag K, Ozisik Y, et al. Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients. Tohoku J Exp Med. 2004;203:205–210
  5. Mickiewicz E. A promising second line treatment with weekly paclitaxel in anthracycline recurrent, advanced breast cancer patients. Proc Am Soc Clin Oncol. 1999;18:135a;[abstract 515]
  6. Seidmann AD, Hudis CA, Albanell J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of advanced breast cancer. J Clin Oncol. 1998;16:3353–3361
  7. Sola C. Phase II study of weekly paclitaxel treatment in recurrent breast cancer after high-dose chemotherapy. Proc Am Soc Clin Oncol. 1999;18:65a;[abstract 245]
  8. Waintraub SE, Cantwell S, DeVries J. Phase II study to evaluate the efficacy of weekly paclitaxel in patients with advanced breast cancer who have failed prior anthracyclines±taxane therapy. Proc Am Soc Clin Oncol. 1999;18:138a;[abstract 530]
  9. Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev. 2004;30:333–342
  10. Perez EA, Vogel L, Irwin D, et al. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat. 2002;73:85–88
  11. Ten Tije AJ, Smorenburg CH, Seynaeve C, et al. Weekly paclitxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicenter phase II trial. Eur J Cancer. 2004;40:352–357
  12. Tabernero J, Climent A, Lluch A, et al. A multicentre, randomised phase II study of weekly or three-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004;9:1358–1365
  13. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000;18:1212–1219
  14. Löffler T, Dröge C, Hausamen TU. Dose dense weekly docetaxel in metastatic breast cancer. Breast Cancer Res Treat. 1999;57:125;[abstract 527]
  15. Ford HE, Yap YS, Miles D, et al. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006;58:809–815
  16. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2002;13:286–292
  17. Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2001;12:1393–1398
  18. Warm M, Nawroth F, Ohlinger R, et al. Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer. Onkologie. 2007;30:436–441
  19. Climent MA, Ruiz A, Llombart-Cussac A, et al. Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activities results. Proc Am Soc Clin Oncol. 1999;18:119a;[abstract 453]
  20. Hainsworth JD, Burris H, Yardley D, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II Trial. J Clin Oncol. 2001;19:3500–3505
  21. D’hondt R, Paridaens R, Wildiers H, et al. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs. 2004;4:341–346
  22. X Ellis RE: the distribution of active bone marrow in the adult. Phys Med Biol 1961;255–8.
  23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(February(3)):205–216
  24. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis. 1961;13(4):346–353
  25. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663–1671
  26. Quaglia A, Tavilla A, Shack L, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer. 2009;6:1006–1016

☆ The safety data in this study were presented at the 9th SIOG meeting on Geriatric Oncology in Montreal, Canada on 18 of October 2008. The trial was also presented as a poster at the 31st Annual San Antonio Breast Cancer Symposium, Texas, 10–14 December 2008.

PII: S1040-8428(09)00137-1

doi: 10.1016/j.critrevonc.2009.07.001

Critical Reviews in Oncology / Hematology
Volume 75, Issue 1 , Pages 70-77 , July 2010

Article Tools

* Image Usage & Resolution